Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
Vascular endothelial growth factors (VEGF), Vascular endothelial growth factor receptors (VEGFR) and their downstream signaling pathways are promising targets in anti-angiogenic therapy. They constitute a crucial system to regulate physiological and pathological angiogenesis. In the last 20 years, m...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1307860/full |
| _version_ | 1827391231658819584 |
|---|---|
| author | Lei Wang Lei Wang Wang-Qing Liu Sylvain Broussy Bingnan Han Hongming Fang |
| author_facet | Lei Wang Lei Wang Wang-Qing Liu Sylvain Broussy Bingnan Han Hongming Fang |
| author_sort | Lei Wang |
| collection | DOAJ |
| description | Vascular endothelial growth factors (VEGF), Vascular endothelial growth factor receptors (VEGFR) and their downstream signaling pathways are promising targets in anti-angiogenic therapy. They constitute a crucial system to regulate physiological and pathological angiogenesis. In the last 20 years, many anti-angiogenic drugs have been developed based on VEGF/VEGFR system to treat diverse cancers and retinopathies, and new drugs with improved properties continue to emerge at a fast rate. They consist of different molecular structures and characteristics, which enable them to inhibit the interaction of VEGF/VEGFR, to inhibit the activity of VEGFR tyrosine kinase (TK), or to inhibit VEGFR downstream signaling. In this paper, we reviewed the development of marketed anti-angiogenic drugs involved in the VEGF/VEGFR axis, as well as some important drug candidates in clinical trials. We discuss their mode of action, their clinical benefits, and the current challenges that will need to be addressed by the next-generation of anti-angiogenic drugs. We focus on the molecular structures and characteristics of each drug, including those approved only in China. |
| first_indexed | 2024-03-08T17:07:40Z |
| format | Article |
| id | doaj.art-4be074a3963d48b48506e3d24abbcff4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-08T17:07:40Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-4be074a3963d48b48506e3d24abbcff42024-01-04T04:24:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122024-01-011410.3389/fphar.2023.13078601307860Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axisLei Wang0Lei Wang1Wang-Qing Liu2Sylvain Broussy3Bingnan Han4Hongming Fang5Department of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou, ChinaZhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, ChinaCiTCoM, CNRS, INSERM, Université Paris Cité, Paris, FranceCiTCoM, CNRS, INSERM, Université Paris Cité, Paris, FranceZhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, ChinaDepartment of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou, ChinaVascular endothelial growth factors (VEGF), Vascular endothelial growth factor receptors (VEGFR) and their downstream signaling pathways are promising targets in anti-angiogenic therapy. They constitute a crucial system to regulate physiological and pathological angiogenesis. In the last 20 years, many anti-angiogenic drugs have been developed based on VEGF/VEGFR system to treat diverse cancers and retinopathies, and new drugs with improved properties continue to emerge at a fast rate. They consist of different molecular structures and characteristics, which enable them to inhibit the interaction of VEGF/VEGFR, to inhibit the activity of VEGFR tyrosine kinase (TK), or to inhibit VEGFR downstream signaling. In this paper, we reviewed the development of marketed anti-angiogenic drugs involved in the VEGF/VEGFR axis, as well as some important drug candidates in clinical trials. We discuss their mode of action, their clinical benefits, and the current challenges that will need to be addressed by the next-generation of anti-angiogenic drugs. We focus on the molecular structures and characteristics of each drug, including those approved only in China.https://www.frontiersin.org/articles/10.3389/fphar.2023.1307860/fullVEGFVEGFRangiogenesisanti-angiogenicinhibitors |
| spellingShingle | Lei Wang Lei Wang Wang-Qing Liu Sylvain Broussy Bingnan Han Hongming Fang Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis Frontiers in Pharmacology VEGF VEGFR angiogenesis anti-angiogenic inhibitors |
| title | Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis |
| title_full | Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis |
| title_fullStr | Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis |
| title_full_unstemmed | Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis |
| title_short | Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis |
| title_sort | recent advances of anti angiogenic inhibitors targeting vegf vegfr axis |
| topic | VEGF VEGFR angiogenesis anti-angiogenic inhibitors |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1307860/full |
| work_keys_str_mv | AT leiwang recentadvancesofantiangiogenicinhibitorstargetingvegfvegfraxis AT leiwang recentadvancesofantiangiogenicinhibitorstargetingvegfvegfraxis AT wangqingliu recentadvancesofantiangiogenicinhibitorstargetingvegfvegfraxis AT sylvainbroussy recentadvancesofantiangiogenicinhibitorstargetingvegfvegfraxis AT bingnanhan recentadvancesofantiangiogenicinhibitorstargetingvegfvegfraxis AT hongmingfang recentadvancesofantiangiogenicinhibitorstargetingvegfvegfraxis |